# Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

> **NCT05455697** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of Washington** · enrollment: 35 (estimated)

## Conditions studied

- Diffuse Large B-Cell Lymphoma
- Grade 3b Follicular Lymphoma
- High Grade B-Cell Lymphoma

## Interventions

- **PROCEDURE:** Bone Marrow Biopsy
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Prednisone
- **BIOLOGICAL:** Retifanlimab
- **BIOLOGICAL:** Rituximab and Hyaluronidase Human
- **BIOLOGICAL:** Tafasitamab
- **DRUG:** Vincristine
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Multigated Acquisition Scan
- **OTHER:** Fludeoxyglucose F-18
- **PROCEDURE:** Positron Emission Tomography
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Polatuzumab Vedotin

## Key facts

- **NCT ID:** NCT05455697
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-26
- **Primary completion:** 2027-01-05
- **Final completion:** 2027-07-06
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05455697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05455697, "Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05455697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*